Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


The Efficacy and Safety of S-ketamine in Elective Cesarean Section: a Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04657107

Organisation Name: Beijing Obstetrics and Gynecology Hospital

Overal Status: Not yet recruiting

Start Date: December 1, 2020

Last Update: December 8, 2020

Lead Sponsor: Beijing Obstetrics and Gynecology Hospital

Brief Summary: During the past years, a large number of clinical trials have investigated the use of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist racemic ketamine as an adjunct to local anaesthetics, opioids, or other analgesic agents for the management and prevention of postoperative pain. Actually racemic ketamine not only abolishes peripheral afferent noxious stimulation, but can also prevent the central nociceptor sensitization. S-ketamine, one of two enantiomers of racemic ketamine, has twice the analgesic potency of the racemate. Moreover, S-ketamine shows smaller nervous system and less psychotropic effects than racemic ketamine , which may make the drug more suitable for clinical use. Recently, S-ketamine has been approved to treat refractory depression (TRD) and major depressive disorder (MDD) by the FDA .S-ketamine may have greater clinical significance due to the high rate of maternal depression. Therefore, we plan to explore whether clinical use of S-ketamine can optimize anesthesia protocol and improve maternal prognosis.

Conditions:
  • Anesthesia
  • Analgesia
  • Depression
  • Cesarean Section
  • Parturition


Total execution time in seconds: 0.19874000549316